Should sodium-glucose cotransporter-2 inhibitors be first-line treatment for patients with type 2 diabetes?
- 5 April 2020
- journal article
- editorial
- Published by CMA Impact Inc. in CMAJ : Canadian Medical Association Journal
- Vol. 192 (14), E375-E376
- https://doi.org/10.1503/cmaj.200426
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort studyCMAJ : Canadian Medical Association Journal, 2020
- Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysisPLoS Medicine, 2019
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsThe Lancet, 2019
- Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of PhysiciansAnnals of Internal Medicine, 2017
- Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 DiabetesAnnals of Internal Medicine, 2016
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.1998